Sangamo to regain full rights to haemophilia A gene therapy programme following Pfizer's decision to cease development ...
Sangamo Therapeutics, Inc., a genomic medicine company, announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe …